Acorda to conduct additional late-stage trial for its MS drug

Reuters - USA
Dec 8 (Reuters) - Acorda Therapeutics Inc. ... In September, the
company had reported positive data from its earlier late-stage trial
of the drug, Fampridine-SR. ...

---

NeuroVax(TM)

The Immune Response Corporation Announces That Previously Approved ...
Genetic Engineering News (press release) - New Rochelle,NY,USA
... In particular, IRC expects to inject the first patient with
NeuroVax(TM) in the next month and is looking forward to
seeing interim 36-week data early next ...

---

Fingolimod

Medical scientists study new drug for MS
Tampa Bay Business Journal - Tampa,FL,USA
... such as MS, has led us to participate in this study sponsored by
Novartis that will examine the use of a new investigational drug called
fingolimod," said Dr ...

---

Fampridine <> Acorda Therapeutics To Initiate Additional Phase 3 Trial Of ...
Trading Markets - Los Angeles,CA,USA
(ACOR | charts | news | PowerRating) on Friday said it would design
and conduct an additional Phase 3 trial of Fampridine-SR in people
with MS. ...

StreetInsider.com Pre-Open Movers 12/08
StreetInsider.com (subscription) - Birmingham,MI,USA
... ACOR) 10% LOWER; said based on feedback it received in
a meeting with the FDA it will design and conduct an additional
Phase 3 trial of Fampridine-SR in people ...

---

Tysabri

2006 - A Very Good Year In MS Research
Medical News Today (press release) - UK
... The FDA approved the return to market of Tysabri(R)
(natalizumab, produced by Biogen Idec and Elan Pharmaceuticals)
to delay the accumulation of physical ...

---